Assessment of clinical usefulness of Procalcitonin (PCT) measurement in pneumonia patients

Assessment of clinical usefulness of Procalcitonin (PCT) measurement in pneumonia patients - Assessment of PCT measurement in pneumonia patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003368

Enrollment

300

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

community-acquired pneumonia, hospital-acquired pneumonia, healthcare-associated pneumonia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pneumonia patients who comply the existence of new infiltration shadow in chest X-rays or CT with at least one of inflamatory (1) and clinical (2) findings below: (1) Inflammatory findings - Fever: 37&#730;C or higher (axillary measurement) - Leukocytosis (WBC> 10,000/mm3) or stab cells > 15% or leukopenia (WBC < 4500/mm3) - CRP positive (2) Clinical findings - Cough - Existence of purulent sputum or airway secreta, or deterioration of properties of sputum observed. - Abnormal auscultation and percussion findings (moist rale, dullness on percussion, reduced respiratory sound, etc.) - Dyspnea, hyperpnea, increased respiratory rate (> 30 / min), whichever is aggravated - Hypoxemia

Exclusion criteria

Exclusion criteria: 1) Patients already administered antibacterial agents for pneumonia before sample collection 2) Other patients judged to be inappropriate by the attending physician

Design outcomes

Primary

Measure	Time frame
1) Assessment of relation between severity and PCT values in each CAP, HAP and HCAP. As indicators of severity, A-DROP and PSI systems are used for CAP, IROAD and PSI systems for HAP and A-DROP, IROAD and PSI systems for HCAP patients. 2) Assessment of relation between currently available inflammatory markers and PCT values in each CAP, HAP and HCAP patients. Inflammatory markers used as comparators: CRP, white blood cell count (WBC) 3) Assessment of relation between patient prognosis and PCT values in each CAP, HAP and HCAP patients. 4) Assessment of relation between causative pathogens and PCT values in each ach CAP, HAP and HCAP patients. 5) Examination of current status and profiles of HCAP. Differences between HCAP and CAP or HCAP will be compared in patient characteristics, laboratory findings and agents for initial treatment.	—

Measure

Time frame

1) Assessment of relation between severity and PCT values in each CAP, HAP and HCAP. As indicators of severity, A-DROP and PSI systems are used for CAP, IROAD and PSI systems for HAP and A-DROP, IROAD and PSI systems for HCAP patients. 2) Assessment of relation between currently available inflammatory markers and PCT values in each CAP, HAP and HCAP patients. Inflammatory markers used as comparators: CRP, white blood cell count (WBC) 3) Assessment of relation between patient prognosis and PCT values in each CAP, HAP and HCAP patients. 4) Assessment of relation between causative pathogens and PCT values in each ach CAP, HAP and HCAP patients. 5) Examination of current status and profiles of HCAP. Differences between HCAP and CAP or HCAP will be compared in patient characteristics, laboratory findings and agents for initial treatment.

—

Countries

Japan

Contacts

Public ContactYoshihiro Yamamoto, MD

Nagasaki University School of Medicine

095-819-7273

Outcome results